Allogene Therapeutics, Inc. Common Stock
Here’s whether Allogene Therapeutics, Inc. Common Stock (ALLO) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); RSI 43 — healthy momentum range; strong 1-year return of +45.7%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.80% over 10 days); 3-month momentum negative (-24.8%). Currently 57.9% off its 52-week high. Score: +1/7.
ALLO is holding above its long-term 200-day MA ($1.72) but has slipped below the 50-day MA ($2.28), pointing to short-term weakness in an otherwise intact trend. An RSI of 43.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +45.7% compares to +24.4% for SPY (beat the market by 21.4%). The current 57.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.